Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4948250 | 1.00 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3KCNH2HRH1 | |
| SCHEMBL3330887 | 0.89 | EPHA2 (0.45) | SLC6A4SLC6A2SLC6A3KCNH2HRH1 | |
| SCHEMBL4935539 | 0.87 | SLC6A2 (0.62) | SLC6A4SLC6A2SLC6A3KCNH2HRH1 | |
| SCHEMBL4935548 | 0.87 | SLC6A2 (0.62) | SLC6A4SLC6A2SLC6A3KCNH2HRH1 | |
| SCHEMBL4942318 | 0.87 | SLC6A2 (0.62) | SLC6A4SLC6A2SLC6A3KCNH2HRH1 | |
| SCHEMBL6355976 | 0.87 | SLC6A2 (0.62) | SLC6A4SLC6A2SLC6A3KCNH2HRH1 | |
| SCHEMBL4943572 | 0.87 | SLC6A2 (0.62) | SLC6A4SLC6A2SLC6A3KCNH2HRH1 | |
| SCHEMBL4942310 | 0.87 | SLC6A2 (0.62) | SLC6A4SLC6A2SLC6A3KCNH2HRH1 | |
| SCHEMBL3329553 | 0.85 | SLC6A4 (0.43) | SLC6A4SLC6A2SLC6A3KCNH2HRH1 | |
| Fumaric Acid SCHEMBL3329551 | 0.79 | SLC6A2 (0.66) | SLC6A4SLC6A2SLC6A3KCNH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | FISH PAUL VINCENT | 2008-07-03 | — | — | US | disclosed |
| EP-1744754-A1 | MORPHOLINE COMPOUNDS | Pfizer Limited (GB) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005105100-A1 | MORPHOLINE COMPOUNDS | PFIZER LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
| US-20050250775-A1 | Novel compounds | FISH PAUL V | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250775-A1 | Novel compounds | OPRL1, UGT1A1, NPSR1 | SLC6A4 114/4885SLC6A2 133/4885SLC6A3 104/4885 |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | OPRL1, MYLK2, TNNT2 | SLC6A4 350/4885SLC6A2 201/4885SLC6A3 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.